1-5 of 5
Lyndah K. Dreiling, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Yong Mun, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Kari G. Chaffee, MS, Richard R. Furman, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jeff Sharman, MD, John F. Seymour, MBBS, PhD, Asher A. Chanan-Khan, MD, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, Lucille A. Ferrante, MD, Lyndah K. Dreiling, MD, Mehrdad Mobasher, MD MPH, Thomas Stark, MD PhD, Vijay Reddy, MD PhD, Angela J. Howes, BSc, PhD, Danelle James, MD MAS, Pankaj Bhargava, MD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4394.
https://doi.org/10.1182/blood-2018-99-112989
Published: 2018
Journal Articles

Risk Factors for Grade 3/4 Transaminase Elevation in Patients with Chronic Lymphocytic Leukemia Treated with Idelalisib

Jennifer R. Brown, MD PhD, Andrew D. Zelenetz, MD PhD, Richard R. Furman, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Marco Montillo, MD, Susan M. O'Brien, MD, Lyndah K. Dreiling, MD, Ronald L. Dubowy, MD, Yeonhee Kim, PhD, Veerendra B. Munugalavada, PhD, Tadeusz Robak, MD PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3016.
https://doi.org/10.1182/blood.V130.Suppl_1.3016.3016
Published: 2017
Journal Articles

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Julie Huang, PhD, Ming Lin, PhD, John C. Byrd, MD, Asher A. Chanan-Khan, MD, Richard R. Furman, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Jeffrey Jones, MD, Jeffrey P. Sharman, MD, Lucille Ferrante, MD, Vijay Reddy, MD PhD, Lyndah K. Dreiling, MD, Henry Adewoye, MD, Ronald Dubowy, MD, Angela Howes, PhD, Danelle F. James, MD MAS, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4303.
https://doi.org/10.1182/blood.V130.Suppl_1.4303.4303
Published: 2017
Journal Articles

Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study

Andrew D Zelenetz, MD, PhD, Tadeusz Robak, MD, PhD, Bertrand Coiffier, MD, PhD, Julio Delgado, MD, Paula Marlton, MBBS, Adeboye H Adewoye, MD, Yeonhee Kim, PhD, Lyndah K. Dreiling, MD, Peter Hillmen, MB, ChB, PhD
Journal: Blood
Blood (2015) 126 (23): LBA-5.
https://doi.org/10.1182/blood.V126.23.LBA-5.LBA-5
Published: 2015
Journal Articles

Evaluation of Single-Dose Palifermin To Reduce Oral Mucositis (OM) in Fractionated Total Body Irradiation (fTBI) and High Dose (HD) Chemotherapy with Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation.

Thomas C. Shea, MD, Tarun Kewalramani, MD, Yong Mun, Gerald Jayne, Lyndah K. Dreiling, MD
Journal: Blood
Blood (2006) 108 (11): 3073.
https://doi.org/10.1182/blood.V108.11.3073.3073
Published: 2006